Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Post-transplant acute myeloid leukemia (PT-AML)
Autore:
Thalhammer-Scherrer, R; Wieselthaler, G; Knoebl, P; Schwarzinger, I; Simonitsch, I; Mitterbauer, G; Berlakovich, GA; Mannhalter, C; Haas, OA; Mayer, G; Muehlbacher, F; Wolner, E; Klepetko, W; Lechner, K; Jaeger, U;
Indirizzi:
UnivaVienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Vienna, Austri Univ Vienna Vienna Austria 1, Div Hematol & Hemostaseol, Vienna, Austri Univ Vienna, Dept Lab Med, Vienna, Austria Univ Vienna Vienna AustriaUniv Vienna, Dept Lab Med, Vienna, Austria Univ Vienna, Dept Surg, Vienna, Austria Univ Vienna Vienna AustriaUniv Vienna, Dept Surg, Vienna, Austria Univ Vienna, Dept Clin Pathol, Vienna, Austria Univ Vienna Vienna Austria iv Vienna, Dept Clin Pathol, Vienna, Austria Univiaienna, Dept Internal Med 3, Div Nephrol & Hemodialysis, Vienna, Austr Univ Vienna Vienna Austria 3, Div Nephrol & Hemodialysis, Vienna, Austr St Annas Children Hosp, CCRI, Vienna, Austria St Annas Children Hosp Vienna Austria ldren Hosp, CCRI, Vienna, Austria
Titolo Testata:
LEUKEMIA
fascicolo: 3, volume: 13, anno: 1999,
pagine: 321 - 326
SICI:
0887-6924(199903)13:3<321:PAML(>2.0.ZU;2-I
Fonte:
ISI
Lingua:
ENG
Soggetto:
RENAL-ALLOGRAFT RECIPIENT; ACUTE MONOCYTIC LEUKEMIA; LYMPHOPROLIFERATIVE DISORDERS; CYCLOSPORINE THERAPY; IMMUNODEFICIENCY; MALIGNANCIES; AZATHIOPRINE; INDUCTION; DISEASES; LYMPHOMA;
Keywords:
solid organ transplantation; acute myeloid leukemia; chemotherapy; immunosuppression; infections;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
40
Recensione:
Indirizzi per estratti:
Indirizzo: Jaeger, U Innere Med Klin 1, Waehringer Guertal 18-20, A-1090 Vienna, Austria Innere Med Klin 1 Waehringer Guertal 18-20 Vienna Austria A-1090
Citazione:
R. Thalhammer-Scherrer et al., "Post-transplant acute myeloid leukemia (PT-AML)", LEUKEMIA, 13(3), 1999, pp. 321-326

Abstract

Acute myeloid leukemia following organ transplantation (PT-AML) is a rare event with only a few published cases in the literature. We present three patients who developed AML (FAB M1, M5, M4) after renal, double lung or liver transplantation. Molecular analysis detected a t(9;11) in one patient anddocumented the recipient origin of AML in a second patient. All patients were treated with chemotherapy. Immunosuppression was reduced to cyclosporinA (CsA) and prednisone in two patients and to prednisone alone in one patient. Two patients achieved a complete remission (CR), with a remission duration of 4.6 months in one patient, the other patient died from septicemia after 15.2 months in CR. One patient was refractory to chemotherapy and diedfrom septicemia. This report together with the documented cases in the literature suggests that PT-AML (1) develops after a median interval of 5 years after transplantation with variable latency (range, <1-17 years); (2) is heterogeneous with respect to FAB classification; (3) shows chromosomal andmolecular changes typical of therapy-related AML (t-AML: -7, +8, 11q23, inv16, t(15;17)); (4) standard chemotherapy is feasible after reduction of immunosuppression and produces a CR rate of 56% with a median remission duration of 4.6 months and an overall survival of 2.6 months; (5) the major complications are early death (25%), Gram-negative septicemia, progressive disease or relapse. This review provides diagnostic and therapeutic experiencesand guidelines for the management of this increasing group of post-transplant patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 02:03:12